Pyr-T

Pyr-T
Names
	Preferred IUPAC name 3-[2-(Pyrrolidin-1-yl)ethyl]-1H-indole
	Other names N,N-Tetramethylenetryptamine
Identifiers
CAS Number	14008-96-9 ;
3D model (JSmol)	Interactive image;
ChemSpider	24588 ;
PubChem CID	26393;
UNII	VZ689W7HWX ;
CompTox Dashboard (EPA)	DTXSID00161226 ;
	InChI InChI=1S/C14H18N2/c1-2-6-14-13(5-1)12(11-15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2 Key: CVTZCBLFHNGYDQ-UHFFFAOYSA-N ; InChI=1/C14H18N2/c1-2-6-14-13(5-1)12(11-15-14)7-10-16-8-3-4-9-16/h1-2,5-6,11,15H,3-4,7-10H2 Key: CVTZCBLFHNGYDQ-UHFFFAOYAE;
	SMILES c2c(c1ccccc1[nH]2)CCN3CCCC3;
Properties
Chemical formula	C14H18N2
Molar mass	214.312 g·mol−1
Melting point	193 to 194 °C (379 to 381 °F; 466 to 467 K) (HCl salt.)
Boiling point	170 to 180 °C (338 to 356 °F; 443 to 453 K) (Freebase at 0.05mm/Hg.)
log P	2.74410
Vapor pressure	1.02x10−5mmHg
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.

Pyr-T (N,N-tetramethylenetryptamine) is a lesser-known, possible psychedelic drug. Pyr-T was first characterized by S. Mitzal.^[1] Toxicity testing was later performed by Hunt and Brimblecombe, and although a lethal dosage was found in rats, a value is not given.^[2] In the book TiHKAL (Tryptamines I Have Known and Loved), neither the dosage nor the duration are reported.^[3]^[4]

Pyr-T produces few to no effects in humans, but some behavioral changes were observed in animal tests.^[2] Very little data exists about the pharmacological properties, metabolism, and toxicity of pyr-T.

References

^ Mitzal, S. (1962). "N/A". Dissertationes Pharm. 14: 305.
^ ^a ^b Hunt, R. R.; Brimblecombe, R. W. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry. 10 (4): 646–648. doi:10.1021/jm00316a027. PMID 4962512.
^ Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL, The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 577–578. ISBN 0-9630096-9-9. Retrieved 7 April 2018.
^ Krasowski MD, Ekins S. Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. J Cheminform 6, 22 (2014). doi:10.1186/1758-2946-6-22

This psychoactive drug-related article is a stub. You can help Wikipedia by expanding it.

[1] Mitzal, S. (1962). "N/A". Dissertationes Pharm. 14: 305.

[Hunt-2] Hunt, R. R.; Brimblecombe, R. W. (July 1967). "Synthesis and Biological Activity of Some Ring-Substituted Tryptamines". Journal of Medicinal Chemistry. 10 (4): 646–648. doi:10.1021/jm00316a027. PMID 4962512.

[3] Shulgin, Alexander; Shulgin, Ann (1997). TiHKAL, The Continuation (1st ed.). Berkeley, CA, USA: Transform Press. pp. 577–578. ISBN 0-9630096-9-9. Retrieved 7 April 2018.

[4] Krasowski MD, Ekins S. Using cheminformatics to predict cross reactivity of “designer drugs” to their currently available immunoassays. J Cheminform 6, 22 (2014). doi:10.1186/1758-2946-6-22

[1]

[2]

[3]

[4]

See also

References